Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets.
The role of seasonal influenza vaccination in pandemic influenza A H1N1 disease is important to address, because a large segment of the population is vaccinated annually. We administered 1 or 2 doses of pandemic H1N1 vaccine (CA/7 ca), a seasonal trivalent inactivated (s-TIV), or live attenuated influenza vaccine (s-LAIV) to mice and ferrets and subsequently challenged them with a pandemic H1N1 virus. In both species, CA/7 ca was immunogenic and conferred complete protection against challenge. s-TIV did not confer protection in either animal model, and s-LAIV did not confer any protection in ferrets. In mice, 2 doses of s-LAIV led to complete protection in the upper respiratory tract and partial protection in the lungs. Our data indicate that vaccination with the seasonal influenza vaccines did not confer complete protection in the lower respiratory tract in either animal model, whereas the CA/7 ca vaccine conferred complete protection in both animal models.
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA.
Grace L
GL
Chen
Ji-Young
JY
Min
Elaine W
EW
Lamirande
Celia
C
Santos
Hong
H
Jin
George
G
Kemble
Kanta
K
Subbarao
D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D004195:Disease Models, Animal; D005260:Female; D005289:Ferrets; D007117:Immunization, Secondary / Q000379:methods; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D008168:Lung / Q000821:virology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009296:Nasal Cavity / Q000821:virology; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D014611:Vaccination / Q000379:methods; D019562:Viral Load
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007252:Influenza Vaccines
J Virol. 2010 Jan;84(1):44-51
19864389
Lancet. 2009 Dec 19;374(9707):2072-2079
19913290
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20365-70
19918065
PLoS Med. 2006 Sep;3(9):e360
16968127
Euro Surveill. 2009 Aug 06;14(31):
19660248
J Infect Dis. 2010 Apr 1;201(7):1000-6
20170374
MMWR Morb Mortal Wkly Rep. 2009 Nov 13;58(44):1241-5
19910912
PLoS Med. 2010 Apr 06;7(4):e1000258
20386731
Virology. 2003 Feb 1;306(1):18-24
12620793
J Infect Dis. 1982 Mar;145(3):320-30
6977595
Euro Surveill. 2009 Aug 20;14(33):
19712643
Sci Transl Med. 2009 Dec 23;1(12):12re1
20371459
J Infect Dis. 1991 Feb;163(2):300-4
1988512
N Engl J Med. 2009 Jun 18;360(25):2605-15
19423869
J Virol. 2005 Sep;79(17):11014-21
16103152
Virology. 2008 Aug 15;378(1):123-32
18585748
N Engl J Med. 2009 Nov 12;361(20):1945-52
19745214
J Infect Dis. 2000 Mar;181(3):1133-7
10720541
Science. 2009 Jul 10;325(5937):197-201
19465683
J Infect Dis. 1994 Jan;169(1):68-76
8277200
Med J Aust. 2009 Aug 3;191(3):146-9
19645642
J Virol. 2009 Jan;83(1):65-72
18945773
J Virol. 2008 Feb;82(3):1350-9
18032492
Virus Res. 2004 Jul;103(1-2):177-85
15163507
Vaccine. 1999 Dec 10;18(9-10):899-906
10580204
Expert Rev Vaccines. 2004 Dec;3(6):643-54
15606348
J Infect Dis. 2010 Oct 1;202(7):1011-20
20715930
J Virol. 2010 Jan;84(1):21-6
19828604
BMJ. 2009 Oct 06;339:b3928
19808768
MMWR Morb Mortal Wkly Rep. 2009 Aug 28;58(33):913-8
19713879